E2 ModeratePreliminaryPEM requiredObservationalPeer-reviewedMachine draft
Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infection.
Guo, Lihui, Appelman, Brent, Mooij-Kalverda, Kirsten et al. · EBioMedicine · 2023 · DOI
Quick Summary
This study found that people with long-COVID have persistent activity of an enzyme called IDO2 in their blood cells and brain tissue, months or years after initial infection. This enzyme breaks down tryptophan (an amino acid) into other compounds that may trigger cellular stress and energy problems. The researchers also discovered that blocking a specific receptor (called AHR) could stop this process in laboratory tests, suggesting a potential treatment target.
Why It Matters
This research identifies a potential biological mechanism underlying PASC/long-COVID—prolonged activation of a tryptophan-degrading enzyme that persists long after viral clearance. Discovery that AHR antagonists can suppress this pathway in vitro opens a novel therapeutic avenue that could be tested to alleviate fatigue, post-exertional malaise, and cognitive dysfunction in ME/CFS and PASC populations.
Observed Findings
- IDO2 is expressed and metabolically active in PBMC and brain tissue from PASC patients months to years after SARS-CoV-2 infection.
- PASC patients show reduced mitochondrial respiratory capacity, depleted intracellular amino acids, and reduced Krebs cycle metabolites in blood cells.
- Autophagy markers are elevated in PBMC from PASC patients in association with IDO2 activity.
- Specific kynurenine metabolites (products of tryptophan degradation) are elevated in PASC plasma and correlate with disease severity.
- An AHR (aryl hydrocarbon receptor) antagonist suppressed both IDO2 expression and autophagy ex vivo in PASC PBMC.
Inferred Conclusions
- SARS-CoV-2 infection triggers persistent IDO2 expression and tryptophan catabolism that is not resolved during normal recovery.
- The specific pattern of kynurenine metabolites generated may determine symptom severity in PASC patients.
- IDO2-driven metabolic stress and autophagy may contribute to mitochondrial dysfunction and cellular energy depletion observed in PASC.
- The AHR pathway represents a potentially targetable mechanism for halting IDO2-mediated pathology.
Remaining Questions
- Does elevated IDO2 activity cause PASC symptoms, or is it a marker of underlying immune dysregulation? Which specific kynurenine metabolites are most pathogenic, and what are their mechanisms?
What This Study Does Not Prove
This study does not prove that IDO2 activity directly causes PASC symptoms, only that it is present and correlates with cellular stress markers. It does not establish whether AHR antagonists would be effective or safe in patients (only ex vivo efficacy was shown). The cross-sectional design cannot determine whether IDO2 activation is a primary driver or a secondary consequence of immune dysregulation.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionFatigue
Biomarker:MetabolomicsGene ExpressionBlood Biomarker
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:Small SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →